Characterising the castration-resistant prostate cancer population: A systematic review

International Journal of Clinical Practice

Volumn 65, Issue 11, 2011, Pages 1180-1192

  Kirby, M ^a   Hirst, C ^b   Crawford, E D ^c  

^a Prostate Centre   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; DOCETAXEL; OPIATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID; STRONTIUM 89;

BIBLIOGRAPHIC DATABASE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL OBSERVATION; DISEASE COURSE; EMBASE; EPIDEMIOLOGICAL DATA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDLINE; METHODOLOGY; NOMENCLATURE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION;

ADULT; AGE OF ONSET; AGED; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 80054690379     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02799.x     Document Type: Review

References (29)

1. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D,. Cancer statistics, 2010. CA Cancer J Clin 2011; 61: 69-90.
2. Ferlay J, Parkin DM, Steliarova-Faucher E,. Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Heidenreich A, Aus G, Bolla M, Joniau S, et al., European Association of Urology Guidelines on Prostate Cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
4. Albertsen PC, Hanley JA, Gleason DF, Barry MJ,. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980. (Pubitemid 28445095)
5. Chodak GW, Thisted RA, Gerber GS, Johansson JE, et al., Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-248. (Pubitemid 24034136)
6. NICE. National Institute for Health and Clinical Excellence Guidelines: prostate cancer: diagnosis and treatment. London, UK: National Collaborating Centre for Cancer, 2008.
7. Crawford ED, Petrylak D,. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol 2010; 28: e408.
8. Guidelines on prostate cancer: European Association of Urology, 2009. Available from: (Accessed 31 March 2010).
9. Alemayehu B, Buysman E, Parry D, Becker L, Nathan F,. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010; 13: 351-361.
10. Berruti A, Mosca A, Porpiglia F, Bollito E, et al., Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 2007; 178: 838-843 [quiz 1129]. (Pubitemid 47211059)
11. Morgan C, McEwan P, Chamberlain G, Cabrera C, Parry D,. Castration-resistant prostate cancer (CRPC): a UK epidemiology study. Value Health 2010; 13: A26 [abstract PCN17].
12. Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, et al., Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003; 1: 242-247. (Pubitemid 37021461)
13. Inoue T, Segawa T, Kamba T, Yoshimura K, et al., Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009; 73: 1104-1109.
14. Berruti A, Tucci M, Mosca A, Tarabuzzi R, et al., Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 2005; 93: 633-638. (Pubitemid 41486453)
15. Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, Arndt JW, et al., Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2004; 31: 958-963. (Pubitemid 38915650)
16. Chin SN, Wang L, Moore M, Sridhar SS,. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 2010; 17: 24-29.
17. Smith MR, Kabbinavar F, Saad F, Hussain A, et al., Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925. (Pubitemid 46224110)
18. Hwang SS, Chang VT, Alejandro Y, Mulaparthi S, et al., Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center. Cancer Invest 2004; 22: 849-857. (Pubitemid 39665349)
19. Sullivan PW, Mulani PM, Fishman M, Sleep D,. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2007; 16: 571-575. (Pubitemid 46474953)
20. Cabrera C, Hirst C, Hayflinger C, Koo L,. Co-morbidity among hormone resistant prostate cancer patients in the US. Pharmacoepidemiol Drug Safety 2010; 19 (A615): S1-S347.
21. Antonarakis ES, Eisenberger MA,. Expanding treatment options for metastatic prostate cancer. N Eng J Med 2011; 364: 2055-2058.
22. Halabi S, Vogelzang NJ, Ou SS, Small EJ,. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol 2007; 177: 531-534. (Pubitemid 46054021)
23. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA,. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 2009; 115: 4470-4476.
24. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, et al., Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162-167.
25. Altekruse SF, Kosary CL, Krapcho M, Neyman N, et al., SEER cancer statistics review, 1975-2007, Bethesda, MD: National Cancer Institute, based on November 2009 SEER data submission, posted to the SEER web site, 2010. 2010.
26. Kato I, Severson RK, Schwartz AG,. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer 2001; 92: 2211-2219.
27. Daniell HW, Dunn SR, Ferguson DW, Lomas G, et al., Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
28. Daniell HW,. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-444. (Pubitemid 27026812)
29. Baker J, Ajani J, Scotte F, Winther D, et al., Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009; 13: 49-59.